File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Long‐term data on entecavir treatment for treatment‐naive or lamivudine‐resistant chronic hepatitis B infection in kidney transplant recipients

TitleLong‐term data on entecavir treatment for treatment‐naive or lamivudine‐resistant chronic hepatitis B infection in kidney transplant recipients
Authors
KeywordsEntecavir
Hepatitis B
Kidney transplantation
Long-term
Issue Date2019
PublisherWiley-Blackwell Publishing, Inc. The Journal's web site is located at http://onlinelibrary.wiley.com/journal/10.1111/%28ISSN%291399-3062/homepage/News.html
Citation
Transplant Infectious Disease, 2019, article no. e13143 How to Cite?
AbstractIntroduction: Entecavir (ETV) showed short‐term efficacy and safety in HBsAg‐positive kidney transplant recipients (KTRs), but long‐term data are lacking. Methodology: We retrospectively reviewed 30 HBsAg‐positive KTRs who received ETV during 2007‐2017. Results: Eighteen treatment‐naïve (Group I) and 12 lamivudine‐resistant (Group II) patients received ETV for 48.4 ± 35.2 and 66.0 ± 26.0 months, respectively. Both groups show significant HBV DNA decline, but Group I achieved earlier undetectability after 11.9 ± 9.6 months (compared with 28.8 ± 24.2 months in Group II, P = .033). Group I showed higher rates of undetectable HBV DNA (89%, 94%, 94%, 100%, and 100% at 12, 24, 36, 48, and 60 months, respectively, compared with 25%, 50%, 50%, 91%, and 91% in Group II, P = .003). ALT normalized after 6.0 ± 1.9 and 6.8 ± 2.1 months in Group I and Group II, respectively. Four patients (33.3%) in Group II developed drug resistance (2 had persistent viraemia and 2 had virological breakthrough, at 40.3 ± 15.0 months). Group II showed higher liver stiffness after 5 years (7.7 ± 4.1 kPa, compared with 5.0 ± 1.6 kPa in Group I, P = .046) and incidence of cirrhosis (4 patients [33.3%], compared with 1 [5.6%] patient in Group I, P = .049). Two patients (one in each group) developed hepatocellular carcinoma. Renal allograft function remained stable during follow‐up of 63.2 ± 33.4 months for both groups. There was no difference in patient and graft survival between two groups at 5 years (P = .62 and .36, respectively). Conclusion: ETV showed favorable long‐term efficacy and tolerability in treatment‐naïve KTRs. One‐third of lamivudine‐resistant subjects showed non‐response or viral breakthrough after ETV treatment.
Persistent Identifierhttp://hdl.handle.net/10722/272277
ISSN
2017 Impact Factor: 1.869
2015 SCImago Journal Rankings: 0.720

 

DC FieldValueLanguage
dc.contributor.authorYap, DYH-
dc.contributor.authorTang, C-
dc.contributor.authorFung, JYY-
dc.contributor.authorSeto, WK-
dc.contributor.authorMa, MKM-
dc.contributor.authorChoy, BY-
dc.contributor.authorChan, TM-
dc.date.accessioned2019-07-20T10:39:08Z-
dc.date.available2019-07-20T10:39:08Z-
dc.date.issued2019-
dc.identifier.citationTransplant Infectious Disease, 2019, article no. e13143-
dc.identifier.issn1398-2273-
dc.identifier.urihttp://hdl.handle.net/10722/272277-
dc.description.abstractIntroduction: Entecavir (ETV) showed short‐term efficacy and safety in HBsAg‐positive kidney transplant recipients (KTRs), but long‐term data are lacking. Methodology: We retrospectively reviewed 30 HBsAg‐positive KTRs who received ETV during 2007‐2017. Results: Eighteen treatment‐naïve (Group I) and 12 lamivudine‐resistant (Group II) patients received ETV for 48.4 ± 35.2 and 66.0 ± 26.0 months, respectively. Both groups show significant HBV DNA decline, but Group I achieved earlier undetectability after 11.9 ± 9.6 months (compared with 28.8 ± 24.2 months in Group II, P = .033). Group I showed higher rates of undetectable HBV DNA (89%, 94%, 94%, 100%, and 100% at 12, 24, 36, 48, and 60 months, respectively, compared with 25%, 50%, 50%, 91%, and 91% in Group II, P = .003). ALT normalized after 6.0 ± 1.9 and 6.8 ± 2.1 months in Group I and Group II, respectively. Four patients (33.3%) in Group II developed drug resistance (2 had persistent viraemia and 2 had virological breakthrough, at 40.3 ± 15.0 months). Group II showed higher liver stiffness after 5 years (7.7 ± 4.1 kPa, compared with 5.0 ± 1.6 kPa in Group I, P = .046) and incidence of cirrhosis (4 patients [33.3%], compared with 1 [5.6%] patient in Group I, P = .049). Two patients (one in each group) developed hepatocellular carcinoma. Renal allograft function remained stable during follow‐up of 63.2 ± 33.4 months for both groups. There was no difference in patient and graft survival between two groups at 5 years (P = .62 and .36, respectively). Conclusion: ETV showed favorable long‐term efficacy and tolerability in treatment‐naïve KTRs. One‐third of lamivudine‐resistant subjects showed non‐response or viral breakthrough after ETV treatment.-
dc.languageeng-
dc.publisherWiley-Blackwell Publishing, Inc. The Journal's web site is located at http://onlinelibrary.wiley.com/journal/10.1111/%28ISSN%291399-3062/homepage/News.html-
dc.relation.ispartofTransplant Infectious Disease-
dc.subjectEntecavir-
dc.subjectHepatitis B-
dc.subjectKidney transplantation-
dc.subjectLong-term-
dc.titleLong‐term data on entecavir treatment for treatment‐naive or lamivudine‐resistant chronic hepatitis B infection in kidney transplant recipients-
dc.typeArticle-
dc.identifier.emailYap, DYH: desmondy@hku.hk-
dc.identifier.emailTang, C: csotang@hkucc.hku.hk-
dc.identifier.emailFung, JYY: jfung@hkucc.hku.hk-
dc.identifier.emailSeto, WK: wkseto@hku.hk-
dc.identifier.emailMa, MKM: h9914584@graduate.hku.hk-
dc.identifier.emailChoy, BY: choybyc@hkucc.hku.hk-
dc.identifier.emailChan, TM: dtmchan@hkucc.hku.hk-
dc.identifier.authorityYap, DYH=rp01607-
dc.identifier.authorityFung, JYY=rp00518-
dc.identifier.authoritySeto, WK=rp01659-
dc.identifier.authorityChan, TM=rp00394-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1111/tid.13143-
dc.identifier.pmid31282041-
dc.identifier.scopuseid_2-s2.0-85069826458-
dc.identifier.scopusWOS:000476847200001-
dc.identifier.hkuros299493-
dc.identifier.spagearticle no. e13143-
dc.identifier.epagearticle no. e13143-
dc.publisher.placeDenmark-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats